Partial quantitative deficiency of von Willebrand factor

Type 1C von Willebrand disease

Qualitative defects of von Willebrand factor

Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers

Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss

Qualitative defects of von Willebrand factor with hyper-adhesive forms

Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb

Qualitative defects of von Willebrand factor with defective platelet adhesion with a normal size distribution of von Willebrand factor multimers

Qualitative defects of von Willebrand factor with defective von Willebrand factor to factor VIII binding

Qualitative defects of von Willebrand factor with markedly decreased affinity for factor VIII

Qualitative defect in von Willebrand factor function, with no further subtyping

(Near) complete absence of von Willebrand factor

Total quantitative deficiency of von Willebrand factor

Acquired von Willebrand syndrome

Platelet-type von Willebrand disease

Pseudo-von Willebrand disease

Hemophilia C

Plasma thromboplastin antecedent [PTA] deficiency

Rosenthal's disease

AC globulin deficiency

Congenital afibrinogenemia

Deficiency of factor I [fibrinogen]

Deficiency of factor II [prothrombin]

Deficiency of factor V [labile]

Deficiency of factor VII [stable]

Deficiency of factor X [Stuart-Prower]

Deficiency of factor XII [Hageman]

Deficiency of factor XIII [fibrin stabilizing]

Dysfibrinogenemia (congenital)

Hypoproconvertinemia

Owren's disease

Proaccelerin deficiency

Autoimmune hemophilia

Autoimmune inhibitors to clotting factors

Secondary hemophilia

Lupus anticoagulant (LAC) with hemorrhagic disorder

Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder

Antithromboplastinemia

Antithromboplastinogenemia

Hemorrhagic disorder due to intrinsic increase in antithrombin

Hemorrhagic disorder due to intrinsic increase in anti-VIIIa

Hemorrhagic disorder due to intrinsic increase in anti-IXa

Hemorrhagic disorder due to intrinsic increase in anti-XIa

Drug-induced hemorrhagic disorder

Hemorrhagic disorder due to increase in anti-IIa

Hemorrhagic disorder due to increase in anti-Xa

Hyperheparinemia

Deficiency of coagulation factor due to liver disease

Deficiency of coagulation factor due to vitamin K deficiency

Primary hypercoagulable states

Factor V Leiden mutation

Antithrombin III deficiency

Hypercoagulable state NOS

Primary hypercoagulable state NEC

Primary thrombophilia NEC

Protein C deficiency

Protein S deficiency

Thrombophilia NOS

Other hypercoagulable states

Anticardiolipin syndrome

Antiphospholipid antibody syndrome

Lupus anticoagulant

Presence of systemic lupus erythematosus [SLE] inhibitor

COVID-19 associated hypercoagulability

Hypercoagulable states NEC

Secondary hypercoagulable state NOS

COVID-19 associated coagulopathy